Sagimet Biosciences Inc. (SGMT) NASDAQ
8.60
+2.74(+46.76%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
8.60
+2.74(+46.76%)
Currency In USD
Address
155 Bovet Road
San Mateo, CA 94402
United States of America (the)
Phone
650-561-8600
Website
Sector
Healthcare
Industry
Biotechnology
Employees
14
First IPO Date
July 17, 2023
| Name | Title | Pay | Year Born |
| David A. Happel | Chief Executive Officer, President & Director | 906,164 | 1962 |
| Thierry Chauche | Chief Financial Officer & Principal Accounting Officer | 598,045 | 1976 |
| Eduardo Bruno Martins DPhil | Chief Medical Officer | 669,064 | 1963 |
| Lucas Pelkmans | Co-Founder | 0 | N/A |
| Urs Greber | Co-Founder | 0 | N/A |
| Marie O'Farrell | Chief Scientific Officer | 0 | N/A |
| Robert D'Urso | Senior Vice President of New Products | 0 | N/A |
| Elizabeth Rozek | Chief Legal & Administrative Officer | 0 | 1971 |
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.